Antiviral Therapeutics
Cross-source consensus on Antiviral Therapeutics from 1 sources and 5 claims.
1 sources · 5 claims
Uses
How it works
Risks & contraindications
Evidence quality
Highlighted claims
- Combined use of hydroxychloroquine and azithromycin compounds QTc prolongation risk and can trigger torsades de pointes. — COVID-19: Treatment, Pathophysiology, and Clinical Management — Clinical Q&A
- Retrospective studies on hydroxychloroquine cannot be considered definitive evidence without randomized controlled trial confirmation. — COVID-19: Treatment, Pathophysiology, and Clinical Management — Clinical Q&A
- Remdesivir is most likely to benefit patients if given early, but is typically administered to ventilated patients whose viral replication has already peaked. — COVID-19: Treatment, Pathophysiology, and Clinical Management — Clinical Q&A
- Azithromycin's putative benefit in COVID-19 is likely due to anti-inflammatory properties rather than its antibiotic mechanism, which is irrelevant to viral infection. — COVID-19: Treatment, Pathophysiology, and Clinical Management — Clinical Q&A
- Ivermectin prevents SARS-CoV-2 from disabling host immune signaling by blocking the nuclear import mechanism the virus exploits. — COVID-19: Treatment, Pathophysiology, and Clinical Management — Clinical Q&A